CN103992274A - Method for synthesizing selective non-steroidal anti-inflammatory and analgesic Celebrex - Google Patents
Method for synthesizing selective non-steroidal anti-inflammatory and analgesic Celebrex Download PDFInfo
- Publication number
- CN103992274A CN103992274A CN201410157853.6A CN201410157853A CN103992274A CN 103992274 A CN103992274 A CN 103992274A CN 201410157853 A CN201410157853 A CN 201410157853A CN 103992274 A CN103992274 A CN 103992274A
- Authority
- CN
- China
- Prior art keywords
- compound
- celebrex
- steroidal anti
- condition
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a method for synthesizing a selective non-steroidal anti-inflammatory and analgesic Celebrex. The method is characterized in that Celebrex with the chemical name of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1-hydro-pyrazol-1-yl]benzenesulfonamide is synthesized at room temperature by adopting a compound 1 and a compound 2 as raw materials, lithium hydroxide as an alkali and ethylene glycol dimethyl ether as a solvent. The method has the advantages of simple operation, mild reaction conditions and high yield, and is a new effective Celebrex synthesis method.
Description
Technical field
The present invention relates to field of medicine and chemical technology, be specifically related to the synthetic method of a kind of selectivity non_steroidal anti_inflammatory drug Celebrex (celecoxib).
Background technology
Celecoxib (Celecoxib, 1) is the COX-2 selective depressant of first listing, its chemistry 4-[5-(4-aminomethyl phenyl)-3-(trifluoromethyl)-1-hydrogen-pyrazol-1-yl by name] benzsulfamide, by Searle company, developed.By selectivity, suppress cyclooxygenase-2 (COX-2) and suppress prostaglandin(PG) generation, reach anti-inflammatory, analgesic effect.Because it can not suppress to have the physiology enzyme of pipe intestinal protection effect--cyclooxygenase-1 (COX-1), gastrointestinal side effect risk is starkly lower than traditional non_steroidal anti_inflammatory drug.Therefore, this medical instrument has gi tract and the advantage such as Toxicity of Kidney is little, is mainly used in the treatment of the diseases such as rheumatic arthritis and osteoarthritis, is called as super acetylsalicylic acid.
At present about the synthetic method of celecoxib, mainly contain the synthetic method (equation as shown in Figure 2) of US5521207 and WO2003024400 (equation as shown in Figure 3) etc.
Accompanying drawing explanation
Fig. 1 is a kind of celecoxib synthetic method equation designing in the present invention.
Fig. 2 is celecoxib synthetic method equation in US5521207.
Fig. 3 is celecoxib synthetic method equation in WO2003024400.
Concrete operations are implemented
To filling in the flask of glycol dimethyl ether (7mL), add compound 1 (626mg, 1.0mmol) and compound 2 (760mg, 2.0mmol).Complete molten after, add lithium hydroxide (70mg, 2.7mmol).Reaction is at stirring at room 12h.HPLC detects raw material 1 and disappears, and reacts completely.Concentration of reaction solution, crosses the separated (elutriant: heptane/ethyl acetate=1: 1), obtain 210mg white solid product, productive rate 77% (equation as shown in Figure 1) of post.
1H?NMR(300MHz,DMSO-d
6):7.88(dt,J=8.8,J=2.3,2H),7.76(dd,J=8.7,2.3,2H),7.72(s,2H),7.29-7.13(m,7H),2.32(s,3H),MS(m/z)for?MH
+(C
17H
16F
3N
3O
2S):caic:382.0837;found:382.1。
Claims (5)
1. the present invention relates to the synthetic method of a kind of non_steroidal anti_inflammatory drug Celebrex (celecoxib), its synthetic method is that to take compound 1 and compound 2 be raw material, is dissolved in suitable organic solvent, and mineral alkali is done alkali, under room temperature condition, aftertreatment obtains target product.
2. method according to claim 1, is characterized in that compound 1 and compound 2 material molar ratios are 1.0: 1.0; 1.0: 1.5; 1.0: 2.0; 1.0: 2.5; 1.0: 3.0 etc., its more excellent condition was second 1.0: 2.0.
3. the method for weighing according to claim 1, is characterized in that its organic solvent used can be acetonitrile, acetone, and Isosorbide-5-Nitrae-dioxane, tetrahydrofuran (THF) etc., it is glycol dimethyl ether compared with enemy condition.
4. the method for claim 1, is characterized in that its mineral alkali used can be sodium hydroxide, calcium hydroxide, and potassium hydroxide, and lithium hydroxide, its more excellent condition is lithium hydroxide.
5. the method for claim 1, is characterized in that selecting under room temperature condition and reacts, and the reaction times can be 4h, 8h, and 12h, 16h, 24h, its more excellent condition is 12h.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410157853.6A CN103992274A (en) | 2014-04-18 | 2014-04-18 | Method for synthesizing selective non-steroidal anti-inflammatory and analgesic Celebrex |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410157853.6A CN103992274A (en) | 2014-04-18 | 2014-04-18 | Method for synthesizing selective non-steroidal anti-inflammatory and analgesic Celebrex |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103992274A true CN103992274A (en) | 2014-08-20 |
Family
ID=51306642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410157853.6A Pending CN103992274A (en) | 2014-04-18 | 2014-04-18 | Method for synthesizing selective non-steroidal anti-inflammatory and analgesic Celebrex |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103992274A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105753783A (en) * | 2016-04-08 | 2016-07-13 | 李文淏 | Method for synthesizing celecoxib |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024400A2 (en) * | 2001-09-18 | 2003-03-27 | Onconova Therapeutics, Inc. | Process for the preparation of 1,5-diarylpyrazoles |
WO2003024958A2 (en) * | 2001-09-18 | 2003-03-27 | Onconova Therapeutics, Inc. | Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles |
CN101084194A (en) * | 2004-12-21 | 2007-12-05 | 默克公司 | Mitotic kinesin inhibitors |
CN103102306A (en) * | 2013-02-06 | 2013-05-15 | 河南东泰制药有限公司 | Preparation method for celecoxib |
-
2014
- 2014-04-18 CN CN201410157853.6A patent/CN103992274A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024400A2 (en) * | 2001-09-18 | 2003-03-27 | Onconova Therapeutics, Inc. | Process for the preparation of 1,5-diarylpyrazoles |
WO2003024958A2 (en) * | 2001-09-18 | 2003-03-27 | Onconova Therapeutics, Inc. | Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles |
CN101084194A (en) * | 2004-12-21 | 2007-12-05 | 默克公司 | Mitotic kinesin inhibitors |
CN103102306A (en) * | 2013-02-06 | 2013-05-15 | 河南东泰制药有限公司 | Preparation method for celecoxib |
Non-Patent Citations (1)
Title |
---|
AIXUE SUN ET AL: "A new efficient synthesis of pyrazoles from hydrazonoyl halides and β-oxophosphonates", 《TETRAHEDRON LETTERS》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105753783A (en) * | 2016-04-08 | 2016-07-13 | 李文淏 | Method for synthesizing celecoxib |
CN105753783B (en) * | 2016-04-08 | 2017-12-15 | 李文淏 | A kind of method for synthesizing celecoxib |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI353970B (en) | ||
Shahrasbi et al. | Design, synthesis and biological evaluation of new Imidazo [2, 1-B] thiazole derivatives as selective COX-2 inhibitors | |
CN105218448A (en) | A kind of synthetic method of 1-methyl-3-difluoromethyl-4-pyrazole carboxylic acid | |
Feng et al. | Selective transformations of 2-(p-toluenesulfonyl)-N-tosylhydrazones to substituted 1, 2, 3-thiadiazoles | |
WO2015012110A1 (en) | Method for manufacturing c-glycoside derivative | |
CN103992274A (en) | Method for synthesizing selective non-steroidal anti-inflammatory and analgesic Celebrex | |
Cai et al. | Access to α, α-difluoro (arylthio) methyl oxetanes from α, α-difluoro (arylthio) methyl ketones and trimethylsulfoxonium halides: scope, mechanism and applications | |
CN103265470B (en) | A kind of synthetic method of silodosin dialkylate | |
JP2007246396A (en) | Manufacturing method of 5-difluoromethoxy-4-thiomethylpyrazole compound | |
TWI403504B (en) | Method for producing 2-haloimidazole compound | |
JP2005510479A (en) | Process for preparing substituted isoxazoles and substituted 2-isoxazolines | |
BRPI0608383B1 (en) | method for producing a nicotinic acid derivative or salt thereof | |
Yang et al. | Regioselective nucleophilic addition of 3-aryl-5-difluoromethyl-isoxazoles to aldehydes | |
CN103755657A (en) | Preparation method of rivaroxaban intermediate | |
CN114751868B (en) | Diaryl substituted triazole acetic acid compound, and preparation method and application thereof | |
CN110845348A (en) | Preparation method of ARV-110 intermediate | |
Guravaiah et al. | Facile polyethylene glycol (PEG-400) promoted synthesis of some new heteryl (E)-styryl sulfones | |
CN104370833A (en) | Preparation method of 1,4-disubstituted triazole derivative | |
JP6771775B2 (en) | Method for producing 2-aminonicotinic acid benzyl ester derivative | |
CN104151276A (en) | Preparation method of metabolic impurity of dronedarone hydrochloride | |
CN104292180A (en) | Preparation method of oxadiazole derivative | |
CN103992273A (en) | Synthesis method of selective non-steroidal anti-inflammatory and analgesic drug Celebrex | |
JP2013129616A (en) | Brominating agent and application of the same | |
CN104059022A (en) | Method for preparing 2,4,5-trinitroimidazole | |
CN104098529A (en) | Method for utilizing inorganic metal sulfide to promote reaction of carbon disulfide and 2-halogen phenylamine to synthesize 2-mercaptobenzothiazole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140820 |